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The four components that make up the "tetralogy" include: 
• a ventricular septal defect (VSD); 
• pulmonary stenosis (subvalvar, valvar and/or supravalvar); 
• an overriding aorta;  
• right ventricular hypertrophy (RV). 
Tetralogy of Fallot (TOF) is one of the most common congenital heart 
disorders (CHDs). This condition is classified as a cyanotic heart 
disorder, because tetralogy of Fallot results in an inadequate flow of 
blood to the lungs for oxygenation (right-to-left shunt) (see the 
following image). Patients with tetralogy of Fallot initially present with 
cyanosis shortly after birth. The mortality rate in untreated patients 
reaches 50% by age 6 years, but in the present era of cardiac surgery, 
children with simple forms of tetralogy of Fallot enjoy good long-term 
survival with an excellent quality of life. 
Complete Intracardiac Repair 
Primary correction is the ideal operation for treatment of tetralogy of 
Fallot (TOF) and is usually performed under cardiopulmonary 
bypass (CPB). The aims of the surgery are to close the ventricular 
septal defect (VSD), resect the area of infundibular stenosis, and 
relieve the right ventricular (RV) outflow tract obstruction 
(RVOTO). 
 
Temporary or Palliative Surgery 
This surgery improved blood flow to the lungs (a shunt between a 
large artery branching off the aorta and the pulmonary artery. One 
end of the shunt is sewn to the artery branching off the aorta. The 
other end is sewn to the pulmonary artery). A complete repair of the 
four defects was done later in childhood (as in our patient case).  
Reasons of late arrhythmia in patient with repaired tetralogy of Fallot 
 
The incidence of atrial arrhythmias after TOF repair is relatively high, about 30%, including atrial 
fibrillation, flutter, focal or reentrant atrial tachycardia.  
● chronic right ventricular systolic pressure overload and increased end-diastolic pressure resulting 
from pulmonary valve insufficiency lead to increased right atrial pressure, hypertrophy and 
fibrosis. 
● the atriotomy scar provides an anatomical obstacle, which in combination with haemodynamic 
disturbances, causes atrial arrhythmias, mainly typical atrial flutter or re-entrant tachycardia around 
the atriotomy scar.  
● tricuspid insufficiency was the main risk factor for development of atrial fibrillation or flutter.   
Also found that risk factor for the development of atrial arrhythmias is the P wave dispersion in 
different leads. 
● intraventricular conduction is typically prolonged in patients after TOF repair, and characterized by 
the presence of a right bundle branch block, they remain at risk of complete AV block should left 
bundle branch block develop as a result of degenerative changes.   
● Although intra-atrial re-entrant tachycardia is the most common postoperative atrial arrhythmia, 
other possible causes should not be overlooked. These include accessory pathways and 
atrioventricular (AV) nodal re-entrant tachycardia, which are relatively easy targets for treatment 
with radiofrequency ablation.   
 Postoperative Arrhythmias in Tetralogy of Fallot, Hell J Cardiol 46: 2005   
OUR PATIENT 
•Patient N.M.V. 
•39 y. old 
•IT-specialist 
•city resident  
of admission: 05 – September – 2015 
COMPLAINTS 
 
• Periodical palpitation 
• Weakness 
• Discomfort in the chest 
ANAMNESIS MORBI 
- Congenital heart defect - tetralogy of Fallot – was surgically treated in 1984, 1990. Patient 
felt himself well till this year, when after skiing and flight to Georgia in January 2017 he felt 
bad, first time appeared episode of palpitation but after hospital treatment with amiodarone 
31.01.17 sinus rhythm was repaired, received constant therapy with clopidogrel. 
- Usual ECG of patient after Fallot tetralogy surgical repairment can be seen below. The same 
ECG picture patient had before hospitalization in the hospital 06-nov-2017. ECG 
conclusion: sinus rhythm, complete RBBB, left anterior hemi-block. 
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- This time patient felt bad 06-nov-2017 at 4 a.m. in the morning when 
appeared feeling of high heart rate and after patient's words “he stated feel 
where the heart is”. At 10.00 a.m. state of the patient worsened: BP was 
100/70 mm Hg and heart rate around 125 bts in min. Patient called an 
ambulance, on ECG was found paroxysm of atrial fibrillation and patient 
received amiodarone 400mg per oral treatment which had slight effect (heart 
rate decreased only till 100 bts in min).  
  
- In 2.30 p.m. his state still wasn’t improved, patient visited district cardiologist 
and after ECG was taken (paroxysm of AF), received again 200mg of 
amiodarone per oral treatment without effect, by ambulance was delivered to 
ICU of the hospital. 
ANAMNESIS MORBI 
ANAMNESIS VITAE 
• Hereditary diseases are not identified 
• Allergic history is not burdened 
• Childhood infections - chickenpox 
• Sexually transmitted diseases were denied 
• Smoker - no, do not abuse alcohol 
• CV disease family history: nothing 
OBJECTIVE STATUS 
- Conciseness - clear, state – moderate severe, body position - active 
- Patient can orientate himself in place, time, his personality 
- Pale skin and mucosae 
- Thyroid: mild hyperplasia of thyroid, soft, homogenous 
- Musculoskeletal system – left pectoralis major muscle is bigger than right one due to 
postsurgical scar present. Scar in the center of sternum  
- BR – 16-18 /min 
- Lung percussion: no clinically significant changes 
- Lung auscultation: hard breathing 
- Borders of the heart: left border – outside of midclavicular left line on 2 cm 
- Heart auscultation: arrhythmic, eusystolia, heart tones – muffled 
- Pulse – rhythmic, 76 bts/min 
- BP 105 / 80 mm Hg 
- Abdomen: normal size, symmetric, unpainful 
- Liver: normal size, no pain during palpation in right hypochondrium 
- Spleen: normal 
- Pasternatsky symptom – negative from both sides 
- Edemas: absent 
Conclusion: AF (HR-80 bts in min), eusystolia. RBBB. Left anterior LBB hemi - block 
ECG during admission 06-nov-2017 
HOLTER ECG from 10-nov-2017 
Conclusion: 
Average HR in day time – 76, average 
HR in night time – 56 bts in min. 
Circadian index of HR – 135% 
(normal). Max HR -116 bts in min. 
Min HR – 50 bts in min. 
Alternation of correct and non-correct 
atrial fibrillation with complete 
RBBB. Segregated ventricular 
premature contractions: 1 –in day 
time, 4-night time. 
Paired ventricular premature 
contractions at night – 1. 
06/11/17 Normal Range 
Hemoglobin, g/l  156 130 – 160 
Red blood cells, 1012 4.81 4.0 – 5.0  
Ht 47% 40-48% 
White blood cells, 109 9,1 4 - 9 
ESR, mm/h 3 1 -10 
Bands  4% 1.06 – 6% 
Segments  46% 47 – 72% 
Eosinophils  1% 0.5 – 5% 
Monocytes  6% 0.1 – 3% 
Lymphocytes  43% 19 – 37 % 
Platelets  264,6 180-320 
BLOOD COUNT 
Conclusion: lymphocytosis with minimal segments level decreasing 
Patient’s ranges, N 
Glucose, mmol/l 4.9 4.22 – 5.5 
Total bilirubin, mkmol/l 9,0 1,7 – 21 
AST, U/l 28,8 < 37 
ALT, U/l 48,0 < 41 
ALT (from 11/01/17), U/l 51,0 < 41 
Total protein, g/l 76.3 66 - 87 
Creatinine, mkmol/l 102 82 – 106 
Urea, mmol/l 6,6 3,0 – 9,2 
Ca, mmol/l 2.37 2.02 – 2.6 
K, mmol/l 4.59 3.6 – 5.5 
Mg, mmol/l 0.75 0.66 – 1.07 
BIOCHEMISTRY TEST 
DATA 
Conclusion: increased ALT concentrations in the serum as clopidogrel day by day therapy side-effect 
CARDIAC ENZYMES TEST 
DATA 
06-nov-2017 Patient’s ranges, N 
13:00 
CFK-NAC, u/l 88 < 171 
CFK-MB, u/l 12,9 0 - 24 
Conclusion: all is normal ranges 
07-nov-2017 Patient’s ranges, N 
7:00 
CFK-NAC, u/l 62 < 171 
CFK-MB, u/l 10.4 0 - 24 
Patient’s ranges, N 
Total cholesterol, mmol/l 5.03 < 5.2 
VLDL, mmol/l 0.34 < 1.0 
LDL, mmol/l 3,19 < 3.5 
TAG, mmol/l 0,77 < 2.3 
HDL, mmol/l 1,49 ≥ 0.9 
Index of atherogenicity 2.37 < 3.0 
LIPID PROFILE 
Conclusion: all is normal ranges 
HEART ULTRASOUND from 08/11/17                            
Aorta: dilated, cuspids are thickened. Ascending aorta – d 46 (20-37mm). Aortic regurgitation I stage. 
Tricuspid valve – regurgitation II stage. Pulmonary trunk valve – regurgitation I stage, d = 29mm.  
Pressure in pulmonary trunk is 21,0 mm Hg (< 15). Mitral valve – cuspids are thin, M-shaped movements in different 
direction, anterior cuspid in left atrium cavity during systole, regurgitation I stage.  
EF – 75% (N - 55 – 78%). FS – 44% (N - 28 – 44%). 
Left Ventricle: 
FDD – 50 mm (N – 35 – 55mm)  
FSD – 28 mm (N – 23 – 38 mm) 
Posterior wall thickness in systole– 11,2 mm (N – 6 – 13mm). 
Intraventricular septum size in diastole– 12,2 mm ( 6 – 11 mm)  
Right Ventricle: 
Diameter – 33,1 mm (N – 9 – 26 mm)  
Wall thickness – 6,8 mm (N – 3 - 6 mm), thickened. 
Left atrium – not enlarged – 34,1 mm in diameter ( N – till 38 mm) 
Right atrium – dilated – 45,6 mm in diameter (N – 25-37). Interatrial septum – not changed, no defects. 
 
Conclusion: Tetralogy of Fallot surgical repair state. Dilation of ascending part of aorta and aortic root, aortic regurgitation 
I stage. Dilation and hypertrophy of right ventricle and dilation of right atrium. Pulmonary hypertension I degree. 
Tricuspid regurgitation II stage. Mitral valve prolapse I degree, regurgitation I stage. No cardiac thrombus.  
Patient’s ranges, N 
Ab to thyroglobulin, mE/ml 14.0 < 100 
TSH, mkME/ml 2,1 0.23 – 3.4 
THYROID GLAND EXAMINATION 
THYROID ULTRASOUND from 08/11/17 
Left lobe – 43*15,5*15,6mm, volume – 7.3 cm3. Right lobe – 50,8*16,9*17,5 mm. 
Average volume of both lobes – 16.0cm3. Isthmus – 5,0 mm. 
Conclusion: Thyroid gland enlarged, situated in typical place. Homogenous 
parenchyma, granulomatous, with hyper and hypoechogenus areas. No volumetric 
growth found. 
Conclusion: all is normal ranges 
ABDOMINAL ULTRASOUND from 08/11/17                            
Liver: Right lobe – 132,5 (N-till 150mm), left lobe thickness -73,8 (N- till 65mm) 
Increased echogenicity, structure is homogenous. Ductular system is not changed. 
Gall bladder: 76,2*19,5 mm. Wall thickness is increased, normal shape, homogenous 
contain with small calculi 1-1,5 mm long, pair of them – 6mm long. 
Pancreas: head – 22,2 mm (N-24-30mm), tail – 29 mm (N – 17-28), body – 18,2 mm 
(N-12-17). Increased parenchyma echogenicity, homogenous. Ductular system is not 
changed. 
Spleen: 39.7*102.5cm. Normal echogenicity, structure is homogenous. 
Right kidney: 100.5*40.2mm, V=82cm/c, normal echogenicity, structure is 
homogenous, not changed. 
Left kidney: 103.7*40.9mm, V=84cm/c, normal echogenicity, structure is homogenous, 
not changed. 
Conclusion: Diffuse changes of pancreas parenchyma. Slight hepatomegaly. Calculous 
chronic cholecystitis.  
COMPLETE DIAGNOSIS of our patient is: 
 
Main: Acquired heart defect: tetralogy of Fallot, state after radical correction 
(1984, 1990). Complete RBBB, left anterior LBB hemi - block. Atrial fibrillation, 
persistent form, paroxysm 06-nov-2017. Dilation of ascending aorta, right heart 
chambers. Tricuspid valve regurgitation II degree, pulmonary trunk valve 
regurgitation I degree. Chronic Heart Failure 0 stage 
 
 
Concomitant diseases: Chronic calculous cholecystitis. Thyroid hyperplasia I 
degree, euthyroid state. 
MEDICATIONS PRESCRIBED IN 
HOSPITAL 
• clopidogrel 75 mg 1 time\day  
• enoxaparinum natrium 0,8ml (80mg) 2 times a day subcutaneous 
• rivaroxaban 20 mg 1 time\day 
• carvedilol 6,25 mg 2 times/day 
• amiodaron 200 mg 3 times a day with HR control 
• asparginat K-Mg 20,0 ml on 100ml of Ringer’s solution 0,9% IV 1 time\day  
• pantoprazol 40 mg 2 times\day 
• tiotriazolin (metabolic) 4,0 ml IV 1 time\day  
Choice of rhythm control therapy following treatment failure 
Despite treatment prescribed (improvement of symptoms, decreased HR <110), patient still has atrial 
fibrillation and rhythm wasn’t  restored.  
• Patient has enlargement and changes in thyroid gland structure. Would be reasonable to recommend thyroid 
hormones evaluation before surgical treatment (TSH, T3, T4 levels) to disapprove thyroid function alteration as 
a cause of AF appearance. 
• Clinical risk scores for bleeding: CHA2DS2-VASc=1,  HASBLED=1, EHRA=II. Patent was recommended to 
continue therapy with rivaroxaban 20 mg /daily for stroke prevention. 
• Long-term pharmacological rate control with beta-adrenoreceptor blocker carvedilol 6,25 *2 times/daily in 
combination with amiodarone 200 mg 2 times/daily (a target heart rate ,80 b.p.m. at rest and ,110 b.p.m. during 
moderate exercise) 
• Consultation of arhythmologist and synchronized direct current electrical cardioversion (and is the method of 
choice in severely haemodynamically compromised patients with new-onset AF). Pre-treatment with 
amiodarone (requiring a few weeks of therapy) can improve the efficacy of electrical cardioversion.  
• For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum of 3 weeks 
before cardioversion. 
• Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who 
have symptomatic recurrences of AF on antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, 
propafenone, sotalol) and who prefer further rhythm control therapy, when performed by an electrophysiologist 
who has received appropriate training and is performing the procedure in an experienced centre.  
RECOMMENDATIONS: 
CONCLUSION 
   Cardiac surgery has transformed the outcome for patients with tetralogy of Fallo. 
However, there are problems with late morbidity and mortality primarily due to right 
ventricular dysfunction, exercise intolerance, arrythmia, and sudden cardiac death. The 
most common form seen in patients with tetralogy of Fallot is atrial fibrillation 
although atrial flutter and other forms of atrial arrhythmias also occur.  
   Despite good progress in the management of patients with atrial fibrillation, this 
arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and 
cardiovascular morbidity, which requires not only heart rate control but also prevention 
of tromboembolic complications. In other words, the main violin played leading role in 
tetralogy Fallo patient health’s piece will be atrial fibrillation which should be managed 
accourding to the latest guidelines for its  management.  
 
 

